Ethicon wraps up $3.4bn acquisition of robotic medical company Auris Health

Ethicon acquisition of Auris Health : Johnson & Johnson’s subsidiary Ethicon has wrapped up its previously announced $3.4 billion acquisition of California-based robotic medical company Auris Health.

Ethicon acquisition of Auris Health

Based on the achievement of certain predetermined milestones, the deal will see additional contingent payments made by Ethicon worth up to $2.35 billion. The deal was announced in February 2019 and was completed after securing antitrust clearance and satisfying other customary closing conditions.

Auris Health develops robotic technologies, which are initially focused on lung cancer. The company boasts of an FDA-cleared platform – the Monarch Platform robotic technology that is being used in bronchoscopic diagnostic and therapeutic procedures.

The Monarch Platform features an instinctive controller interface to enable physicians to navigate the flexible robotic endoscope to the lung periphery. Bronchoscopic visualization and also access to patient airways for diagnostic and therapeutic procedures are offered by the Monarch Platform and its accessories.

Ethicon acquisition of Auris Health is therefore expected to enable Johnson & Johnson to advance its capabilities in combating lung cancer and to grow its digital surgery portfolio across multiple surgical specialties.

The Monarch Platform robotic technology is also expected to have a key role within the Lung Cancer Initiative at Johnson & Johnson (LCI), to facilitate the development of a differentiated digital solution that addresses important steps in the lung cancer care journey, right from diagnosis to early-stage intervention.

Ashley McEvoy – Executive Vice President, Worldwide Chairman, Medical Devices, Johnson & Johnson, commenting on Ethicon acquisition of Auris Health, said: “We are focused on building a connected, data-driven digital ecosystem that pairs our market-leading surgical solutions with advanced technologies to improve the patient experience.

“The passionate team and differentiated innovation from Auris will help us amplify the power of digital surgery to address unmet clinical needs and lead a transformation in surgical care and lung cancer intervention.”

Johnson & Johnson further stated that Auris Health’s technology complements the robotic platform technologies that are being developed in general surgery with Verb Surgical, through its collaboration with Verily, and in orthopedics through the acquisition of Orthotaxy through its French affiliate Apsis last year.

Related posts

• Pfizer lung cancer drug Vizimpro bags CHMP’s positive opinion (0)
• InventisBio out-licenses lung cancer drug D-0316 to Betta Pharma (0)
• Amgen seeks FDA approval for infliximab biosimilar ABP 710 (0)
• Janssen depression medication esketamine nasal spray yields mixed results in phase 3 trial (0)
• Janssen bags EC approval for daratumumab for multiple myeloma (0)
• FDA approves IMBRUVICA, rituximab combo for rare blood cancer (0)
• CHMP recommends AstraZeneca lung cancer drug Imfinzi EMA approval (0)
• AstraZeneca lung cancer drug Tagrisso gets FDA breakthrough therapy designation (0)
• Men who take vitamin B supplements at greater risk of lung cancer (0)
• Merck lung cancer drug Keytruda plus chemo gets FDA approval for NSCLC (0)

The post Ethicon wraps up $3.4bn acquisition of robotic medical company Auris Health appeared first on PharmaNewsDaily.com.